Academician Wu Chengwen of Academia Sinica publishes "Inheritance". The next-generation biomedical solution center cultivates life sciences and brings together industry, academia, research and medicine to create a new look for the Kaohsiung Science Park settlement. Are you worried about invisible bacteria in your life? Shuishen Disinfectant helps you completely eliminate harmful bad bacteria. Jinwanlin’s non-invasive physical testing service makes an appointment for a healthier life?
CellMax Life, a global cancer testing leader with R&D centers in Silicon Valley and Taiwan, USA The technology company, known for its commitment to providing affordable early cancer detection and management solutions to the general public through non-invasive blood testing, today published research at the 2018 American Society of Clinical Oncology Annual Meeting Gastrointestinal Cancer Symposium Clinical Research Results. The abstract of the paper shows that using the CellMax Life patented CMxTM platform to detect circulating tumor cells in the blood (CellMax CTC blood test) can not only detect colorectal cancer early, but also detect early canceration in many clinical cases. Lesions, the detection accuracy reaches 84-88!
Colorectal cancer is preventable! If detected early, the cure rate is very high. However, in Taiwan, colorectal cancer has ranked first among the top ten cancers for nine consecutive years! Traditional colorectal cancer screening methods, such as colonoscopy or stool testing, are invasive or inconvenient, resulting in low public willingness to undergo colonoscopy. As a result, most colorectal cancers are not discovered until it is too late. , unable to achieve the goal of improving survival rate.
Dr. Cai Wensi from Linkou Chang Gung Memorial Hospital and leader of this research project said: "The great significance of this research is that CTCs may be produced in blood circulating tumor cells in early colorectal cancer or precancerous lesions. We The research results show that the CMxTM platform can be used to detect CTCs very sensitively and accurately assess cancer risk, providing a new and convenient method for people who want to be tested regularly but are resistant to colonoscopy or are unwilling to undergo stool testing. Cancer screening options, and this chip platform detection technology can also be used in breast cancer, prostate cancer, lung cancer and other cancer detection in the future."
Circulating tumor cells (CTC) Circulating tumor cells (CTC) come from the process of cancer metastasis. Cancer cells are detached from the original tumor and enter the blood circulation. Circulating tumor cells have long been known to be used to detect cancer, but most current techniques using circulating tumor cells can only detect late-stage cancers. CellMax CTC blood test, also known as "liquid biopsy", can detect these circulating tumor cells in the blood at an early stage. This is one of the first clinical studies to show that the CellMax CTC blood test can effectively detect cancer at an earlier, more treatable stage.
In the paper published this time, the researchers recruited 620 subjects over the age of 20 who voluntarily accepted this study. These included those who went to the hospital for routine medical examinations. Colonoscopy or patients who have been confirmed to have colorectal cancer. After undergoing colorectal endoscopy and pathological tissue sections, 438 subjects were found to have precancerous polyps (pre-cancerous growths) or early to advanced colorectal cancer. The remaining participants had no signs of polyps or colorectal cancer and served as the control group for this clinical study.
The subject only needs to obtain 2 ml of peripheral circulating whole blood through routine blood drawing to detect circulating tumor cells. The blood sample is then processed by the CMx detection platform, and the blood test results and the colorectal endoscopy results are then subjected to blind analysis to obtain the final comparison data.
The results of this clinical study show that the sensitivity of this test is 77% in the group of precancerous lesions in which CTCs are detected, and in the first to fourth stage cancers in which CTCs are detected. There are 87 in the group. After calculating sensitivity and specificity at the same time, the detection accuracy is as high as 84~88 in precancerous lesions and cancer specimens. In addition, the test is more accurate than the fecal occult blood test (FOBT) currently used in colorectal cancer screening guidelines.
The study’s co-author, Dr. Ashish Nimgaonkar, a gastroenterologist and medical director of the Center for Bioengineering Innovation and Design at Johns Hopkins University, said: “CellMax’s circulating tumor cell blood test ( The CellMax CTC blood test can fill the public's need for a test that is both convenient and can accurately detect early-stage colorectal cancer. Since the blood sample of this test only requires routine blood drawing, it can be easily integrated into the general population. Public examination items to increase detection rates. ”
The researchers of this clinical study plan to conduct more clinical studies in Taiwan and extend clinical studies in the United States in the future. Since the mechanism of circulating tumor cell detachment and the detection principle of the CMx? platform are applicable to all solid tumors, it is expected that this platform will provide good results for other solid tumors such as breast cancer, lung cancer and prostate cancer.
Atul Sharan, co-founder and CEO of CellMax Life, said: "Early detection may be the only solution to cancer. In order to be more effective, early cancer screening tests It must be non-invasive, simple, affordable and accurate, and CellMax Life’s Circulating Tumor Cell Blood Test (CellMax CTC blood test) meets all these requirements.” He further pointed out: “Recent surveys show that when invasive treatments are not chosen, More than 80% of patients undergoing colorectal screening prefer blood testing over stool screening. This test could provide patients with an alternative and also increase screening rates."
This clinical study is one of the sub-projects of the Translational Research on Improving Cancer Survival Rates conducted by Linkou Chang Gung Memorial Hospital funded by the Phase II Cancer Research Program of Taiwan’s Ministry of Health and Welfare. The research results will be used in the Phase II study. One of the authors, Dr. Wensi Cai, presented at the 2018 ASCO Gastrointestinal Cancers Symposium held on Saturday, January 20, 2018. Conference attendees can also visit CellMax Life’s booth (#27) and learn more about the research results and applications of CellMax CTC blood test in colorectal cancer.
Topic: Colorectal Cancer